{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:35:51Z","timestamp":1767494151847,"version":"3.40.5"},"reference-count":17,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12,1]]},"abstract":"\n OBJECTIVE:<\/jats:title>\n We assessed the immunogenicity and safety of a combination measles, mump, rubella, and varicella vaccine (MMRV) (ProQuad [Merck & Co, Inc, West Point, PA]) administered to healthy children concomitantly with a pneumococcal 7-valent conjugate vaccine (PCV-7) (Prevnar [Pfizer, Philadelphia, PA]).<\/jats:p>\n <\/jats:sec>\n \n PATIENTS AND METHODS:<\/jats:title>\n Healthy 12- to 15-month-old children who lacked vaccination and clinical histories for measles, mumps, rubella, varicella, and zoster but had written documentation of receipt of a 3-dose primary series of PCV-7 were randomly assigned in a 2:1:1 ratio to receive either the MMRV and PCV-7 (group 1), PCV-7 followed 6 weeks later by MMRV (group 2), or MMRV followed 6 weeks later by PCV-7 (group 3). The primary safety analysis was 56 days (28 days after each visit). Immunogenicity was evaluated 6 weeks after each vaccination.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n A total of 1027 children were enrolled (group 1: 510; group 2: 258; group 3: 259). For all 3 groups, the antibody response rate was \u226596.8% for measles, mumps, and rubella, \u226588.0% for varicella-zoster virus, and \u226598.3% for all of the 7 Streptococcus pneumoniae serotypes. The immune responses to all antigens present in MMRV and PCV-7 were similar whether administered concomitantly or sequentially. The incidence of local and systemic adverse experiences (AEs) was comparable between group 1 and groups 2 and 3 combined. No vaccine-related serious AEs were reported.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS:<\/jats:title>\n Concomitant administration of the MMRV and PCV-7 is highly immunogenic and generally well tolerated. Similar immune responses between the groups support concomitant administration of the MMRV and PCV-7 to healthy children 12 to 15 months of age.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/peds.2010-2132","type":"journal-article","created":{"date-parts":[[2011,11,29]],"date-time":"2011-11-29T05:19:04Z","timestamp":1322543944000},"page":"e1387-e1394","source":"Crossref","is-referenced-by-count":11,"title":["Immunogenicity and Safety of MMRV and PCV-7 Administered Concomitantly in Healthy Children"],"prefix":"10.1542","volume":"128","author":[{"given":"Michael","family":"Leonardi","sequence":"first","affiliation":[{"name":"Palmetto Pediatrics, North Charleston, South Carolina;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Bromberg","sequence":"additional","affiliation":[{"name":"Brooklyn Hospital Center, Brooklyn, New York;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Baxter","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie L.","family":"Gardner","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, North Wales, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Klopfer","sequence":"additional","affiliation":[{"name":"Palmetto Pediatrics, North Charleston, South Carolina;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ouzama","family":"Nicholson","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, North Wales, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Brockley","sequence":"additional","affiliation":[{"name":"i3 Statprobe, Ann Arbor, Michigan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Trammel","sequence":"additional","affiliation":[{"name":"i3 Statprobe, Ann Arbor, Michigan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Leamy","sequence":"additional","affiliation":[{"name":"i3 Research, Cary, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Williams","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, North Wales, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kuter","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, North Wales, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Sch\u00f6del","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, North Wales, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2011,12,1]]},"reference":[{"issue":"10","key":"2021120900392631800_B1","first-page":"258","article-title":"Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2021120900392631800_B2","first-page":"1","article-title":"Measles, mumps, and rubella: vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"47","author":"Watson","year":"1998","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2021120900392631800_B3","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"33","key":"2021120900392631800_B4","first-page":"921","article-title":"National, state, and local area vaccination coverage among children aged 19\u201335 months: United States, 2008","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"2021120900392631800_B5","first-page":"3","article-title":"General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"National Center for Immunization and Respiratory Diseases","year":"2011","journal-title":"MMWR Surveill Summ"},{"issue":"RR-9","key":"2021120900392631800_B6","first-page":"1","article-title":"Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"13","key":"2021120900392631800_B7","first-page":"343","article-title":"Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV-7) in children aged 24\u201359 months who are not completely vaccinated","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"2021120900392631800_B8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jmv.1890320310","article-title":"Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen","volume":"32","author":"Wasmuth","year":"1990","journal-title":"J Med Virol"},{"issue":"2","key":"2021120900392631800_B9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0264-410X(91)90266-9","article-title":"Antibody assays suitable for assessing immune responses to live varicella vaccine","volume":"9","author":"Provost","year":"1991","journal-title":"Vaccine"},{"issue":"2","key":"2021120900392631800_B10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0166-0934(86)90048-0","article-title":"Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies","volume":"14","author":"Keller","year":"1986","journal-title":"J Virol Methods"},{"issue":"4","key":"2021120900392631800_B11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00006454-200204000-00014","article-title":"Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection","volume":"21","author":"Li","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"2021120900392631800_B12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006454-199201000-00006","article-title":"Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response","volume":"11","author":"White","year":"1992","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"2021120900392631800_B13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/CVI.00014-06","article-title":"Enzyme-linked immunosorbent assay for measuring antibodies to pneumococcal polysaccharides for the PNEUMOVAX 23 Vaccine: assay operating characteristics and correlation to the WHO international assay [published correction appears in Clin Vaccine Immunol. 2008;15(6):1034]","volume":"13","author":"Marchese","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"2021120900392631800_B14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"issue":"5","key":"2021120900392631800_B15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.2.5.3246","article-title":"Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad)","volume":"2","author":"Kuter","year":"2006","journal-title":"Hum Vaccin"},{"issue":"34","key":"2021120900392631800_B16","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1016\/j.vaccine.2009.05.056","article-title":"Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting","volume":"27","author":"Jacobsen","year":"2009","journal-title":"Vaccine"},{"issue":"4","key":"2021120900392631800_B17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/01.inf.0000207857.10947.1f","article-title":"Safety and immunogenicity of a measles, mumps, rubella, and varicella vaccine given with combined Haemophilus influenzae type B conjugate\/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines","volume":"25","author":"Shinefield","year":"2006","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/128\/6\/e1387\/844384\/zpe012110e1387.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/128\/6\/e1387\/844384\/zpe012110e1387.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T06:48:59Z","timestamp":1639032539000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/128\/6\/e1387\/31093\/Immunogenicity-and-Safety-of-MMRV-and-PCV-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,1]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,12,1]]},"published-print":{"date-parts":[[2011,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2010-2132","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2011,12,1]]}}}